# A Phase I Trial of ZIO-101 in Hematologic Cancers

> **NCT00592046** · PHASE1 · COMPLETED · sponsor: **Alaunos Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- Acute Leukemia
- Chronic Myeloproliferative Disease
- Chronic Lymphoproliferative Disease
- Multiple Myeloma
- Lymphoma
- Poor-risk Myelodysplasia (MDS)

## Interventions

- **DRUG:** ZIO-101 (Darinaparsin)

## Key facts

- **NCT ID:** NCT00592046
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00592046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00592046, "A Phase I Trial of ZIO-101 in Hematologic Cancers". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00592046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*